196 related articles for article (PubMed ID: 26549805)
21. Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.
Miller KR; Patel JN; Ganapathi MK; Tait DL; Ganapathi RN
Gynecol Oncol; 2016 Jun; 141(3):608-615. PubMed ID: 26957480
[TBL] [Abstract][Full Text] [Related]
22. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
24. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
25. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
Gupta M; Babic A; Beck AH; Terry K
Hum Pathol; 2016 Aug; 54():82-91. PubMed ID: 27068525
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
27. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
[TBL] [Abstract][Full Text] [Related]
28. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
29. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
30. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
31. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.
Wilson AJ; Fadare O; Beeghly-Fadiel A; Son DS; Liu Q; Zhao S; Saskowski J; Uddin MJ; Daniel C; Crews B; Lehmann BD; Pietenpol JA; Crispens MA; Marnett LJ; Khabele D
Oncotarget; 2015 Aug; 6(25):21353-68. PubMed ID: 25972361
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
33. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Oswald AJ; Gourley C
Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
[TBL] [Abstract][Full Text] [Related]
34. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
35. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
37. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
38. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
39. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
40. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]